Astria Therapeutics, INC 8-K filings
Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.
Astria Therapeutics, Inc. has completed its merger with BioCryst Pharmaceuticals, Inc., becoming a wholly-owned subsidiary and delisting from Nasdaq.
Astria Therapeutics stockholders have approved the acquisition by BioCryst Pharmaceuticals, with the merger expected to close around January 23, 2026.
Astria Therapeutics, Inc. is facing two lawsuits alleging negligence and misrepresentation regarding its merger with BioCryst Pharmaceuticals, Inc.
Astria Therapeutics announced its third quarter 2025 financial results and provided a corporate update, including the expected Q1 2026 closing of its acquisition by BioCryst Pharmaceuticals.
BioCryst Pharmaceuticals will acquire Astria Therapeutics for approximately $920 million in cash and stock, expanding its hereditary angioedema portfolio with late-stage asset navenibart.
Astria Therapeutics has licensed its investigational HAE therapy, navenibart, to Kaken Pharmaceutical for development and commercialization in Japan, securing an upfront payment and extending its cash runway into 2028.
Astria Therapeutics, Inc. announced that its stockholders approved all proposals at the Annual Meeting, including the election of Class I directors, ratification of auditors, advisory approval of executive compensation, and a significant increase in shares available under the 2015 Stock Incentive Plan.
Astria Therapeutics reports financial results for Q4 and full year 2024, highlighting progress in clinical trials for Navenibart (STAR-0215) and STAR-0310.
Astria Therapeutics has unveiled the design of its Phase 3 clinical trial, ALPHA-ORBIT, for navenibart, a potential treatment for hereditary angioedema, featuring both 3-month and 6-month dosing regimens.
Astria Therapeutics has increased the number of shares available under its 2022 Inducement Stock Incentive Plan from 1.7 million to 2.8 million to attract new employees.
Astria Therapeutics' stockholders approved an increase of 5,750,000 shares to the 2015 Stock Incentive Plan and elected three Class III directors at their annual meeting on June 5, 2024.
Astria Therapeutics has increased its board size to nine members and appointed Dr. Sunil Agarwal as a new director, effective April 8, 2024.
Astria Therapeutics reports strong initial efficacy data from its Phase 1b/2 trial of STAR-0215 for hereditary angioedema (HAE), showing significant reductions in attack rates and rescue medication use, and plans to move into Phase 3 trials.
Astria Therapeutics has entered into an agreement to sell up to $150 million of its common stock through an at-the-market offering.
Astria Therapeutics has announced the pricing of a $125 million underwritten offering of its common stock to fund research and development activities.
Astria Therapeutics has successfully sold the remaining $50 million of its common stock under its at-the-market offering program, resulting in net proceeds of $48.5 million.